Reltecimod TFA

Description: Reltecimod TFA (AB-103 TFA) is a CD28 (T-lymphocyte receptor) mimetic that acts as a CD28 antagonist, inhibiting the stimulation of t-cells by a range of bacterial pathogens thereby attenuating acute inflammation for the treatment of necrotizing soft tissue infections (NSTI). Target: Immunology/Inflammation related, Antibacterial. Smiles: [H]N[C@@H](C)C(N[C@H](C(N1CCC[C@H]1C(N[C@@H](CCSC)C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)C(C)C)=O)CC(C)C)=O)=O)=O)CO)=O.OC(C(F)(F)F)=O. References: Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669-1683 (2020).